BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalan

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the

On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning,

Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, toppin

BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum an

BioNTech (BNTX), the mRNA vaccine and oncology developer, pulled the plug on its Phase 2 colorectal-

BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate i

BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene c

A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX

BioNTech SE said on Friday it has ​decided to terminate the mid-stage trial ‌of its experimental mRN

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closel

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasda

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closel

Moderna stock is giving back a large chunk of Tuesday's rally. The pullback reopens a question that

Two names built on the same platform have stopped moving together this morning. Moderna (NASDAQ:MRNA

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 7% to $135.22 in Monday morning trading,

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc

The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single tri

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine,

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock are down 18% to $142.70 in Thursday mi

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any

MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will prese

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains

Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vacci

BioNTech SE (NASDAQ:BNTX) stock is trading higher on Wednesday. Investors are probably reacting to M

BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its indi

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

BioNTech has officially named its next CEO. The transition appears carefully planned, not reactive.

https://youtu.be/H_RititNE8U

Bank of New York Mellon Corp lowered its holdings in BioNTech SE Sponsored ADR (NASDAQ: BNTX) by 64.

Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price

Evercore ISI Group analyst Cory Kasimov maintains BioNTech (NASDAQ:BNTX) with a Outperform and lo

BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript

BioNTech NASDAQ: BNTX reported second-quarter 2026 revenue of €106 million, down from €261 million a

BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 bill

BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst conse

BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) announced today that its Su

The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lower

https://www.bloomberg.com/news/articles/2026-06-17/biontech-investor-fortsch-says-founders-spinout-r

UBS analyst David Dai upgrades BioNTech (NASDAQ:BNTX) from Neutral to Buy and raises the price ta

Bernstein analyst Jeffrey Walch initiates coverage on BioNTech (NASDAQ:BNTX) with a Market Perfor

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the

Wells Fargo analyst Mohit Bansal maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers th

https://www.nytimes.com/2026/05/05/us/politics/fda-covid-vaccine-studies.html